Biotech Values

[DonShimoda]

While inhibition of mTORC1 potentially activates an mTOR-dependent survival pathway, dual mTORC1/mTORC2 inhibitors represent just one approach. One could perhaps more effectively address the issue by combining an mTORC1 inhibitor with an Akt or PI3K inhibitor. In fact, Merck presented data at AACR showing "combined inhibition of TORC1 & IGF1R eliminates IRS-1 mediated feedback activation of AKT and enhances PI3K pathway inhibition." The combination of MK-0646 and ridaforolimus significantly enhanced the anti-proliferative activity of MK-0646. So I'm not sure I would write off rida so quickly.